retatrutide clinical trial benefits VisualAbstract: reduces body weight by 17.5% in patients with obesity Today, we shared new data

Employers looking to add GLP-1 drug coverage specifically for weight loss to their health plans will be best-served by working in conjunction with clinical data experts who can help assess benefit design, address potential increases in drug spending, and incorporate healthcare benefits with effective behavioral modification and support programs

"It is unacceptable because time is life

They offer a safe, effective, and structured pathway to clearer, more even-toned skin

Drug Resist Update

Instead, hypoglycemia occurs in a small percentage of patients, but compared with GLP-1 RA, tirzepatide has a dose-dependent risk of hypoglycemia (60, 63)

Licensing compounds without efficacy or safety data doesn't fix that problem, it legitimizes it